tiprankstipranks
Analyst Profile
Followed by 46 other investors
.
Navin Jacob

Navin Jacob

UBS
Wall Street Analyst
Ranked #5,879 out of 8,050 Analysts on TipRanks (#15,748 out of 21,576 overall experts)

Success Rate

46%
17 out of 37 Profitable Transactions

Average Return

-1.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Navin Jacob's ratings since 2018 and opened each position for the duration of 1 Year:
45.95% of your transactions would have been profitable with an average return of -1.6%

Stock Rating Distribution

84Ratings
54.76% Hold
45.24% Buy
0.00% Sell
Distribution of Navin Jacob's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market
CanadaCanadian Market

Best Rating

Stock:
Intercept Pharmaceuticals Inc
(ICPT)
Rating Type:Buy
Dates:Feb 01, 2018 - Feb 01, 2019
Gain:88.00%
The most profitable rating made by Navin Jacob

Navin Jacob's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Vertex Pharmaceuticals
May 30, 2018
Hold
Assigned
50%
+0.85%
3
Regeneron
May 30, 2018
Hold
Assigned
0.00%
3
Incyte
May 30, 2018
Hold
Assigned
0.00%
2
CELG
Celgene
May 30, 2018
Hold
Assigned
0.00%
3
Alnylam Pharma
Jan 23, 2019
Hold
Initiated
$87.00
(-61.72% Downside)
0.00%
1
Zoetis
Mar 20, 2019
Hold
Initiated
$100.00
(-42.59% Downside)
0.00%
2
Viatris
May 28, 2019
Hold
Reiterated
$23.00
(112.57% Upside)
0.00%
2
Teva Pharmaceutical
Aug 16, 2019
Hold
Reiterated
$8.00
(-25.02% Downside)
0%
-45.75%
4
AGN
Allergan
Nov 19, 2019
Hold
Downgraded
100%
+11.70%
2
Elanco Animal Health
Nov 20, 2019
Hold
Reiterated
$28.00
(47.21% Upside)
0.00%
2
List of latest recommendations made by Navin Jacob. Click to expand and see Navin Jacob's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More